This study was designed as a single-center, randomized, open, two-cycle, cross-over trial. It is planned to enroll 18 healthy subjects
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
18
Three Herombopag Olamine Tablets is administered to healthy subjects.
The Second Hospital of Anhui Medical Uniersity
Hefei, Anhui, China
Cmax
Time frame: 0hour to 120hours after the last dosing
AUC0-t
Time frame: 0hour to 120hours after the last dosing
AUC0-∞
Time frame: 0hour to 120hours after the last dosing
Tmax
Time frame: 0hour to 120hours after the last dosing
t1/2
Time frame: 0hour to 120hours after the last dosing
CL/F
Time frame: 0hour to 120hours after the last dosing
V/F
Time frame: 0hour to 120hours after the last dosing
Incidence and severity of adverse events (AEs)
Time frame: from screening to 120 hours after the last dosing
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.